Introducing the New Human MSD® Neurodegeneration 7-Plex Array

Eve Technologies is offering early access to the Human MSD® Discovery Assay® Neurodegeneration 7-Plex Array, enabling simultaneous measurement of seven biomarkers associated with Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative disorders.

This new multiplex assay combines biomarkers of amyloid and tau pathology, neuroaxonal injury, astrocytic activation, and proteins involved in neurodegenerative disease processes. Researchers can investigate multiple aspects of neurodegeneration from a single sample using the ultrasensitive Meso Scale Discovery® (MSD®) platform.

---

Human MSD® Discovery Assay® Neurodegeneration 7-Plex Array

GFAP | NfL | pTau217 | Aβ40 | Aβ42 | LRRK2 | TDP-43

$169.97 per sample | Starting from 50 μL | No minimum sample requirement

For Research Use Only. Not for use in diagnostic procedures.

---

Explore More Neurodegeneration Biomarkers in a Single Assay

Neurodegenerative diseases involve complex and often overlapping biological processes. While individual biomarkers provide valuable information, combining complementary targets can help researchers explore different aspects of disease biology within the same study.

The new Human MSD® Neurodegeneration 7-Plex Array brings together seven biomarkers in a single multiplex immunoassay, providing a broader approach to neurodegeneration research.

By measuring GFAP, NfL, pTau217, Aβ40, Aβ42, LRRK2, and TDP-43 simultaneously, researchers can investigate relationships between multiple biomarker pathways while conserving valuable sample material.

Key Advantages

• Seven biomarkers in one assay: Simultaneous measurement of complementary neurodegeneration-related proteins.
• Ultrasensitive MSD® technology: Electrochemiluminescence-based detection for sensitive protein quantification.
• Low sample volume: Starting from 50 μL for a single analysis or 75 μL for duplicate analysis.
• Flexible sample quantities: From individual samples and pilot studies to large research cohorts, with no minimum order requirement.
• Pay-per-sample testing: Access multiplex biomarker testing without purchasing an entire assay plate.
• Early access: Explore this new biomarker combination through Eve Technologies’ laboratory testing service.

Seven Key Biomarkers for Neurodegeneration Research

The Neurodegeneration 7-Plex Array combines established research biomarkers with emerging targets of interest in neurodegenerative disease research.

Biomarker	Biological Relevance	Research Applications
GFAP – Glial Fibrillary Acidic Protein	A protein associated with astrocytes and astrocytic activation.	Alzheimer’s disease, neuroinflammation, glial responses, and neurodegeneration
NfL – Neurofilament Light Chain	A structural neuronal protein released during neuroaxonal injury.	Neurodegenerative disease progression, neuronal injury, and longitudinal biomarker studies
pTau217 – Phosphorylated Tau 217	A phosphorylated form of tau strongly associated with Alzheimer’s disease-related pathology.	Alzheimer’s disease, tau-related pathology, and biomarker discovery
Aβ40 – Amyloid Beta 40	An amyloid-beta peptide frequently studied alongside Aβ42 to investigate amyloid biology.	Alzheimer’s disease, amyloid metabolism, and Aβ42/Aβ40 research
Aβ42 – Amyloid Beta 42	An aggregation-prone amyloid-beta peptide associated with amyloid plaque pathology.	Alzheimer’s disease, amyloid accumulation, and neurodegenerative disease biology
LRRK2 – Leucine-Rich Repeat Kinase 2	A kinase involved in cellular signaling and lysosomal processes, with genetic and biological links to Parkinson’s disease.	Parkinson’s disease, LRRK2-associated pathways, and neurodegenerative mechanisms
TDP-43 – TAR DNA-Binding Protein 43	An RNA-binding protein implicated in neurodegenerative proteinopathies.	ALS, frontotemporal dementia, LATE, and TDP-43-related neurodegeneration

Together, these seven biomarkers provide opportunities to investigate multiple biological processes, including amyloid and tau pathology, neuronal injury, astrocytic responses, and disease-associated protein pathways.

Applications in Neurodegenerative Disease Research

Alzheimer’s Disease and Dementia Research

Alzheimer’s disease research increasingly incorporates multiple biomarkers to investigate different aspects of disease pathology.

The combination of pTau217, Aβ40, Aβ42, GFAP, and NfL enables researchers to explore amyloid- and tau-associated changes alongside markers of astrocytic activation and neuroaxonal injury.

The inclusion of TDP-43 also provides an additional research target of interest for investigating overlapping neurodegenerative pathology and age-related dementia.

• Relevant biomarkers: pTau217, Aβ40, Aβ42, GFAP, NfL, TDP-43.

Parkinson’s Disease Research

LRRK2 is an important area of investigation in Parkinson’s disease, particularly in studies of genetic susceptibility, kinase signaling, and lysosomal biology.

By combining LRRK2 with biomarkers such as NfL and GFAP, the panel supports research investigating relationships between Parkinson’s disease-associated pathways, neuronal injury, and glial responses.

• Relevant biomarkers: LRRK2, NfL, GFAP.

ALS and Frontotemporal Dementia Research

TDP-43 plays a central role in the pathology of most amyotrophic lateral sclerosis (ALS) cases and many forms of frontotemporal lobar degeneration.

The inclusion of TDP-43 alongside NfL and GFAP creates opportunities for exploratory biomarker studies involving neuroaxonal injury, glial responses, and TDP-43-associated disease processes.

• Relevant biomarkers: TDP-43, NfL, GFAP.

Assay Specifications

Specification	Details
Assay Name	Human MSD® Discovery Assay® Neurodegeneration 7-Plex Array
Assay Code	MSDND7
Technology	Meso Scale Discovery® (MSD®) Electrochemiluminescence
Format	Multiplex immunoassay
Biomarkers	GFAP, NfL, pTau217, Aβ40, Aβ42, LRRK2, TDP-43
Sample Volume – Single Analysis	50 μL
Sample Volume – Duplicate Analysis	75 μL
Price	$169.97 per sample (single analysis)
Minimum Sample Requirement	No minimum sample count
Intended Use	Research Use Only (RUO)
Availability	Early Access

Sample compatibility: Contact our scientific team to confirm the suitability of your sample matrix and project requirements before submitting samples.

Neurodegeneration Biomarker Testing with Eve Technologies

Eve Technologies provides biomarker testing services to researchers worldwide, supporting projects ranging from initial exploratory studies to large-scale research programs.

With more than 20 years in operation and experience supporting research across academic, biotechnology, and pharmaceutical settings, our laboratory helps researchers access specialized immunoassay testing without the need to establish these workflows in-house.

Our Discovery Assays service offers:

• Flexible project sizes: No minimum sample quantity, whether your study contains one sample or a large cohort.
• Pay-per-sample pricing: Test only the samples you need, without purchasing a complete assay plate.
• Multiple immunoassay platforms: Extensive experience with MSD®, Luminex®, and ELISA technologies.
• In-house laboratory testing: Samples are analyzed by our experienced laboratory team.
• Global research support: Biomarker testing services available to researchers worldwide.

Whether you are planning a pilot study, investigating new biomarker combinations, or expanding an existing neurodegeneration research project, our team can help you explore the available testing options.

Frequently Asked Questions

What is the MSD® Neurodegeneration 7-Plex Array?

The Human MSD® Neurodegeneration 7-Plex Array is a multiplex immunoassay offered by Eve Technologies that simultaneously measures seven neurodegeneration-related biomarkers: GFAP, NfL, pTau217, Aβ40, Aβ42, LRRK2, and TDP-43. It uses the ultrasensitive MSD® electrochemiluminescence platform and is available for research use.

Which biomarkers are included in the assay?

The panel includes glial fibrillary acidic protein (GFAP), neurofilament light chain (NfL), phosphorylated tau 217 (pTau217), amyloid beta 40 (Aβ40), amyloid beta 42 (Aβ42), leucine-rich repeat kinase 2 (LRRK2), and TAR DNA-binding protein 43 (TDP-43).

What diseases can this panel be used to study?

The biomarker combination is relevant to research investigating Alzheimer’s disease, Parkinson’s disease, ALS, frontotemporal dementia, and other neurodegenerative conditions. Its individual markers are associated with different disease processes, making the panel useful for exploratory research into overlapping biological pathways.

The assay is intended for research use and is not a clinical diagnostic test.

Can the panel be used for Alzheimer’s disease research?

Yes. The panel contains several commonly studied Alzheimer’s disease-related biomarkers, including pTau217, Aβ40, Aβ42, GFAP, and NfL. It also includes TDP-43, which is of research interest in overlapping neurodegenerative pathology.

Does the panel include both Aβ40 and Aβ42?

Yes. Both amyloid beta 40 and amyloid beta 42 are included, allowing both analytes to be measured within the same multiplex panel. Researchers interested in calculating an Aβ42/Aβ40 ratio should confirm analytical suitability for their sample type and intended analysis.

How much sample volume is required?

The listed sample requirements are 50 μL for single analysis and 75 μL for duplicate analysis. Contact our team to confirm any additional sample preparation or matrix-specific requirements.

Is there a minimum sample requirement?

No. Eve Technologies’ Discovery Assays operate on a flexible pay-per-sample basis, allowing researchers to submit small pilot projects or larger sample cohorts.

Do I need to purchase an entire assay plate?

No. The Discovery Assays service is a laboratory testing service, and researchers pay for the individual samples submitted for analysis.

Is the Neurodegeneration 7-Plex Array available now?

Yes. Eve Technologies currently offers early access to the Human MSD® Neurodegeneration 7-Plex Array. Researchers can review the assay details, request a quote, and submit an order through our website.